Abstract
Introduction: Primary immunodeficiency diseases (PIDs) are under-reported in Malaysia. The actual disease frequency of PID in this country is unknown due to the absence of a national patient registry for PID.
Objective: This systematic review aimed to determine the prevalence rates of PID cases diagnosed and published in Malaysia from 1st of January 1979 until 1st of March 2020. It also aimed to describe the various types of PIDs reported in Malaysia.
Method: Following the development of a comprehensive search strategy, all published literature of PID cases from Malaysia was identified and collated. All cases that fulfilled the International Union of Immunological Societies (IUIS) classification diagnosis were included in the systematic review. Data were retrieved and collated into a proforma.
Results: A total of 4,838 articles were identified and screened, with 34 publications and 119 patients fulfilling the criteria and being included in the systematic review. The prevalence rate was 0.37 per 100,000 population. In accordance with the IUIS, the distribution of diagnostic classifications was immunodeficiencies affecting cellular and humoral immunities (36 patients, 30.3%), combined immunodeficiencies with associated or syndromic features (21 patients, 17.6%), predominant antibody deficiencies (24 patients, 20.2%), diseases of immune dysregulation (13 patients, 10.9%), congenital defects in phagocyte number or function (20 patients, 16.8%), defects in intrinsic and innate immunity (4 patients, 3.4%), and autoinflammatory disorders (1 patient, 0.8%). Parental consanguinity was 2.5%. Thirteen different gene mutations were available in 21.8% of the cases.
Conclusion: PIDs are underdiagnosed and under-reported in Malaysia. Developing PID healthcare and a national patient registry is much needed to enhance the outcome of PID patient care.
Introduction
Primary immunodeficiency diseases (PIDs) or inborn errors of immunity are inherited disorders that impair the immune response, leading to increased risk of infections, immune dysregulation, autoimmune phenomena, inflammation, and malignancy. They are classified as “rare diseases,” but their global incidence is more prevalent than generally thought (1). Six million people are estimated to be living with PIDs worldwide, of which only 27,000–60,000 have been diagnosed (2). Early detection and prompt action by clinicians could reduce complications and save lives by administering appropriate treatment.
Malaysia is a small country situated in Southeast Asia, with a total population of 32.6 million; the total livebirths in 2018 was 501.9 thousand, and the GDP per capita is 10,940 USD. The estimated life expectancy in Malaysia is 74.5 years, and 28% of the population is aged less than 18 years. The under-5 mortality rate was 7.8 deaths per 1,000 live births in 2018 (3).
Management and research of PIDs in Malaysia are met with many challenges. Vast gaps in knowledge of PIDs and translation of diagnosis and management into clinical practice exist. Given the scarce epidemiological PID data and the lack of patient awareness or diagnostic facilities in Malaysia, PIDs are a tremendous challenge for the biomedical community, thereby causing unnecessary suffering, and deaths. Therefore, national studies must be considered to efficiently and systematically assess the proportion of affected individuals amongst the general population (4).
Furthermore, estimates of PIDs frequency in Malaysia are needed to determine the cost-effectiveness of routine screening. Most incidence and prevalence determination is performed using data from national patient registry databases (5, 6). Given the absence of a Malaysian PID registry database, the prevalence rate was calculated in the present paper by systematically reviewing PID literature from Malaysia to provide retrospective data for the medical community, the health authorities, and PID patients and their families and improve the knowledge of PIDs. This systematic review offers a mechanism to describe the epidemiological landscape of PIDs in Malaysia and constitutes an opportunity to determine the prevalence rates of PIDs in a defined non-referred population.
Methods
In these sections, the strategy to identify relevant citations gathered for this review is described, and a summary of the results is provided. A comprehensive search of the Cochrane Library and Medline databases (via PubMed) was initially conducted from its inception to 1st of March 2020. A title/abstract keyword search was conducted, 77 candidate article abstracts were manually reviewed, and forward/backward reference searches were completed. Controlled vocabulary supplemented with keywords (which included autoimmunity) was used to search for individual primary immunodeficiencies in accordance with the IUIS 2019 classification (7). The search results and study selections are outlined in Figure 1. The PICO statement was as follows: P, patients with PID in Malaysia; I, none considering looking into the epidemiology and prevalence study; C, other neighboring Southeast Asian countries and O, prevalence and incidence rates.
Figure 1
Cases were screened using primary immunodeficiencies in accordance with the IUIS 2019 classification (7). For all published papers retrieved, the second, fifth, and sixth author reviewed the title and abstracts independently and performed the selections on the basis of pre-specified inclusion and exclusion criteria. All inclusions and exclusions were discussed and finalized with all team members. The primary author reviewed the clinical profile, laboratory parameters, other comorbid conditions, and other associated factors discussed in the papers and retrieved the relevant information. Age and year at diagnosis were retrieved from the publications. In cases where year was not listed, an assumption that the year of diagnosis was equal to the year of publication was made in specific articles/cases. Attempts were also made to contact the original authors of the included published studies via email in cases of incomplete information or for further clarification. The prevalence rates were calculated by the fourth author. The third author offer critical review on the manuscript draft.
The agreement of reviewers on the methodological quality assessment was assessed, and any disagreement was resolved by discussion or, if agreement could not be reached, by arbitration by the third author. Reviewers were not masked to study details when assessing the study quality.
The period prevalence rate per 100,000 population was calculated as the number of all existing PID cases diagnosed up to 2019, divided by the average number of the Malaysian population over a specified time period.
Results
A total of 4,838 articles were identified and screened in accordance with the pre-determined inclusion criteria. Thirty-four publications and 119 patients were included in this systematic review (Table 1). The study population was mainly Malays (67%), Chinese (14%), Indians (17%), Ibans (1%), and Melanau (1%). However, information regarding race was only available in 84 of 119 cases identified. The mean age was difficult to determine due to the nature of reporting by all the reports. Parental consanguinity was only recorded as present in three cases (2.5%). The pattern of major reporting centers, which were mainly from the public universities and the medical research team, was noted. Out of 63 cases identified with family history mentioned in the publications, only 38% had positive family history. Only two adult patients were reported to have PID (familial hemophagocycytic lymphohistiocytosis) (17), whereas the remaining aged between the 1st month of life and 17 years. However, patient age was only available in 26 publications.
Table 1
| Paper ID | No of Patient/Gender | Age at onset of PID symptoms | Clinical presentation | Ethnicity | Infective agent | Clinical diagnosis | Treatment | Outcome | Genetic diagnosis/family history |
|---|---|---|---|---|---|---|---|---|---|
| (8) | 2 (Male) | Pt 1: 4 month-old | Hematemesis, purpura, eczema, bilateral otitis media | Chinese | Salmonella enteritis, Pseudomonas septicaemia, CMV | Pt 1: Wiskott Aldrich syndrome | – | Died | None. No family history |
| Pt 2: 19 day-old | Staphylococcal sepsis, gastroenteritis, multiple episodes of epistaxis, hematemesis, purpura, rectal bleeding, eczema (at age 2.5 years) | Chinese | Staphylococcal sepsis, Hepatitis B | Pt 2: Wiskott Aldrich syndrome | Levamisole | Died | None. No family history | ||
| (9) | 1 (Male) | 20-month-old | Failure to thrive, multiple abscesses, frequent URTI, bilateral otitis media, scars from pyoderma on his thighs and the rest of his lower limbs | Indian | Staphylococcus aureus, Pseudomonas aeruginosa | Hyper IgM | Aggressive antibiotic therapy including cefuroxime, netilmicin and cotrimoxazole, and IVIG | Died | None |
| (10) | 2 (Male) | Pt 1: 1 week-old | Frequent boils, recurrent urinary tract infection, septicemia, pneumonia, hepatosplenomegaly, cutaneous abscesses, anemic lymphadenopathy and failure to thrive | Malay | Chromobacterium violaceum and Staphylococcus aureus | Chronic Granulomatous Disease | Antibacterial therapy | – | None. Non-consanguineous families. Reported male siblings' death in early infancy, sparing female siblings |
| Pt 2: 11 month-old | Jaundice, anemic, febrile, meningitis, hepatosplenomegaly, cutaneous abscesses, perianal abscesses, pneumonia and lymphadenopathy | Malay | Staphylococcus aureus, Staphylococcus epidermis, E. coli | Chronic Granulomatous Disease | Antibacterial therapy | Died | None | ||
| (11) | 1 (Female) | 12-month-old | Staphylococcal pneumonia left sided empyema. Had scaly skin and recurrent furuncles since aged 2 months old, cryptococcal meningitis | Chinese | E. coli, Staphylococcus aureus, Cryptococcus neoformans | Hyper-IgE syndrome | Prophylactic antibiotics (Fusidic acid, rifampin, ceftazidime, amikacin, intravenous amphotericin B, oral flucytosine | Died | – |
| (12) | 2 (Male) | Pt 1: 2 years old | 2 days history of fever and seizures, mildly jaundiced with generalized lymphadenopathy | – | Flavobacterium meningosepticum | Pt 1: X-linked lymphoproliferative disease (XLP) | Treated with chemotherapy for lymphoma | Died | None. Patients are siblings of non-consanguineous parents |
| Pt 2: 5 years old | 3 days history of fever, sore throat and generalized macular-papular rash, hepatomegaly, splenomegaly, lymphadenopathy | – | EBV | Pt 2: X-linked lymphoproliferative disease (XLP) | – | Died | |||
| (13) | 1 (Female) | 40-day-old | Intermittent fever, hepatosplenomegaly, cytopenia, lymphadenopathy, mildly jaundice | Malay | – | Familial Hemophagocytic Lymphohistiocytoizis | – | Died | None. Consanguineous parents + |
| (14) | 1 (Female) | 3 month- old | Early childhood with recurrent infection of the sinopulmonary tract (recurrent otitis externa and chest infections; multiple cold staphylococcal abscesses of the skin; severe, extensive and pruritic eczematoid lesions of the skin and markedly elevated serum IgE). Coarse facies were not seen. | Chinese | Staphylococcus aureus | Hyper-IgE syndrome | Intravenous vancomycin, cotrimoxazole and fluconazole, IVIG. Intravenous ceftazidime, amikacin, amphotericin B and intensive chest physiotherapy (for lung) | Died | None. Consanguineous family + (her father's grandmother and mother's father are siblings) |
| (15) | 2 | Pt 1 and Pt 2 | Bad impairment of other organ systems (renal failure and coagulopathy, severe pneumonitis, gastro-intestinal hemorrhage and hepatitis), bacteremia | – | Non-typhoidal Salmonella | Pt 1: Combined T and B cell deficiencies | – | Died | None |
| Pt 2: Selective IgA deficiency | |||||||||
| (16) | 3 | Pt 1, 2 and 3 | – | – | – | Wiskott–Aldrich syndrome | – | – | Pt 1(ID = P84): exon 2 missense 290C>T |
| Pt 2(ID = P105a): nonsense exon 4, 400 C>A | |||||||||
| Pt 3 (ID = P168): exon 10 deletion 1115–1119 delc | |||||||||
| (17) | 2 brothers (Males) | Pt 1: 21 years old | Pyrexia of unknown origin, significant weight loss, hepatosplenomegaly | – | – | Familial hemophagocytic lymphohistiocytosis (FHL) | Intravenous cyclophosphamide, etoposide and prednisolone monthly for 6 months; subsequently maintained for oral cyclosporin for 1 year | Responded well to chemotherapy | None |
| Pt 2: Twenties | One month history of fever, weight loss, febrile with herpes simplex infection on lips, multiple indurated plaque like lesion on lower limbs and trunk | - | – | Familial hemophagocytic lymphohistiocytosis (FHL) | Intravenous cyclophosphamide, etoposide and prednisolone monthly for 6 months; subsequently maintained for oral cyclosporin for 1 year | Responded well to chemotherapy | None | ||
| (18) | 2 | – | – | – | – | Familial hemophagocytic lymphohistiocytosis (FHL) | HSCT | – | – |
| (19) | 1 (Male) | 12 years old | Recurrent episodes of sepsis, multi-organ abscesses, infected non-healing ulcer and enlarged axillary lymph nodes | - | Chromobacterium violaceum | CGD | Oral antibiotics ciprofloxacin and cotrimoxazole | Alive | None |
| (20) | 2 (1 Male, 1 Female) | – | – | – | Klebsiella pneumonia bacteremia | Pt 1: SCID | – | Died | None |
| – | – | – | Candidiasis, Klebsiella pneumonia | Pt 2: SCID | – | Died | None | ||
| (21) | 1 (Male) | 2 years old | Recurrent infections with 2 episodes of chicken pox at age 2 years, repeated episodes of pneumonie and bronchiectasis by age 6 years. | Malay | Chicken pox | Partial defective BTK protein expression CD19 deficiency with selective IgM deficiency | IVIG | Alive | CD19 gene exon 1 A homozygous deletion of a C nucleotide (c.24delC) |
| Physical examination revealed gross clubbing with crepitations at both lung bases | |||||||||
| (22) | 2 (Pt 1: Male; | Born 1987 | Meningococcemia, retinitis pigmentosa in the right eye, and a protracted episode that included herpes simplex, left foot cellulitis which grew Chromobacterium violaceum, hepatitis, a gastrointestinal hemorrhage, septicemia and oral candidiasis, discoid lupus erythematosus | Malay | Chromobacterium violaceum | Pt 1: p-47 phox deficient Chronic Granulomatous Disease | – | – | NCF1 |
| Pt 2: Female) | Born 1993 | The affected younger brother-with Chronic Granulomatous Disease- (born 1993), succumbed to Chromobacterium violaceum septicemia complicated by intracranial bleeding just before this study was initiated. | Malay | Chromobacterium violaceum | Pt 2: Chronic Granulomatous Disease | – | Died | None | |
| (23) | 1 (Male) | 27-day-old | Meningitis, BCG lymphadenitis, prolonged fever. Older brother had pneumonia at birth, recovered and well | Chinese | – | X-linked Chronic Granulomatous Disease | – | – | CYBB gene; Non-consanguineous family. |
| Family study where older brother was both an X-linked Chronic Granulomatous Disease carrier and a Klinefelter. | |||||||||
| (24) | 52 patients (Cross-referencing to exclude overlapping cases) | - | The commonest clinical presentation is pneumonia (54%) | Malay (62%), Chinese (13.5%), Indian (23.1%), Iban (2%) | – | Predominant Antibody deficiency (40.4%) Phagocytic defect (17.3%), Combined immunodeficiencies (15.4%) and other cellular immunodeficiencies (11.5%). | – | – | Family history with a close family relative afflicted was a strong pointer to diagnosis for PID (52.6%) |
| (25) | 1 (Male) | 17 years old | Skin lesions, cellulitis, septicemia and microabscesses in the spleen and liver | - | Chromobacterium violaceum | Chronic Granulomatous Disease | Intravenous meropenem with cloxacillin, Emergency laparotomy | Died | – |
| (26) | 1 (Male) | 7 years old | Recurrent pyogenic infection, recurrent otitis media, recurrent bronchopneumonia, failure to thrive | Malay | – | X-linked Agammaglobulinemia with bronchiectasis | IVIG therapy, Inhaler prophylaxis | Alive | Base substitution in the first nucleotide of intron 9 and the mutation was IVS9+1G>C, Absence of BTK expression, circulating B cells and antibodies |
| (27) | 1 (Male) | 6-week-old | Chryseobacterium sepsis, hepatosplenomegaly, pancytopenia, increased histiocytes exhibiting hemophagocytosis, necrotizing enterocolitis | South Indian | Chryseobacterium sepsis | Griscelli syndrome | HLH-2004 protocol, HSCT | Alive | Homozygous mutation in RAB27A exon 6 c.550C>T Parents heterogenous carriers |
| (28) | 2 (Male) | Pt 1: 18 month-old | Clinical features consistent with classic Wiskott Aldrich Syndrome for both patients (thrombocytopenia, eczema, and recurrent infections. | Malay | – | Pt 1: Wiskott–Aldrich syndrome | – | – | Novel mutation of c.28C>T in exon 1/Non-consaguineous parents, mother was carrier |
| Pt 2: 4 month-old | Initial clinical presentations: Bleeding tendency. Thrombocytopenia and low mean platelet volume) | Malay | – | Pt 2: Wiskott–Aldrich syndrome | – | – | Nonsense mutation of c.264C>A in exon 2/ two older brothers died due to sepsis, mother was carrier | ||
| (29) | 1 (Male) | 8 month-old | Complex febrile fit, secondary to right otitis externa, chronic subacute arthritis of both knees | Not mentioned | Pseudomonas aeruginosa | X-linked Agammaglobulinemia | IVIG | Defaulted follow up after discharged from hospital | Base substitution g.36712A>G in the genomic DNA, de-novo splice site resulted in a truncated BTK protein |
| (30) | 1 (Female) | 4-month-old | Mutliple Intestinal Atresia that involved the pyloric, duodenal, jejunal, ileal and colonic segments. Antenatal ultrasound at 7 months of gestation showed polyhydramnios and Multiple Intestinal Atresia | Malay | – | TTC7A SCID | – | Died | Compound heterozygous mutations in TTC7A |
| (31) | 1 (Male) | 3-month-old | Hepatosplenomegaly, bronchopneumonia, multiple granulomas and abscesses in the lungs in the liver and spleen, fever, lymphadenopathy (18 months old) | Melanau | – | Autosomal recessive Chronic Granulomatous Disease | Multiple antibiotics, augmentin, doxycycline, co-trimoxazole and anti-TB (isoniazid, rifampicin and pyrazinamide) | HSCT was done 5 years after diagnosis | NCF1 (Neutrophil Cytolistic Factor 1). Eldest of two siblings of non-consanguineous parents. No family history of PIDs. |
| (32) | 2 | Pt 1: 1 years old | Monocyte with deficit of BTK expression | – | – | Pt 1: X-linked Agammaglobulinemia | IVIG therapy | – | BTK gene mutation, c.1888A>T |
| Pt 2: 2 years old | Monocyte with deficit of BTK expression | – | – | Pt 2: X-linked Agammaglobulinemia | IVIG therapy | – | BTK gene mutation, g.34430_34447 delCAAAGTCATGATgtgagt | ||
| (33) | 6 | – | – | Malay | – | Pt 1: SCID | – | – | SCID |
| – | – | Malay | – | Pt 2: SCID | – | – | SCID | ||
| – | – | Malay | – | Pt 3: IL2RG SCID | – | – | IL2RG SCID | ||
| – | – | Malay | – | Pt 4: SCID | – | – | SCID | ||
| – | – | Malay | – | Pt 5: ADA SCID | – | – | ADA SCID | ||
| – | – | Malay | – | Pt 6: IL2RG SCID | – | – | IL2RG SCID | ||
| (34) | 1 (Female) | 11 years old | High fever, recurrent episodes of diarrhea, oral thrush, and failure to thrive. PID screening showed low T cell, very low B cell counts, and low immunoglobulin levels | – | Cytomegalovirus | Combined T and B cell deficiencies with Cytomegalovirus retinitis | 3 weekly intravenous immunoglobulins, cotrimoxazole prophylaxis, empirical therapy- syrup fluconazole and syrup nystatin, QID, also treated for Cytomegalovirus colitis, completed 6 weeks of intravenous ganciclovir | – | None |
| (35) | 1 (Male) | 10 month-old | Recurrent pneumonia, chronic diarrhea and failure to thrive | Malay | - | IL2RG SCID | Haploidentical HSCT | Alive | Heterozygous c.270-2A>T mutation in intron 2 of the IL2RG gene |
| Non-consanguineous parents | |||||||||
| (36) | 1 (Female) | 4-month-old | Recurrent abscesses over the whole part of the body, recurrent oral candidiasis, growth failure and recurrent pneumonias since 4 months old. She also had history of a few episodes of acute tonsillitis, chronic suppurative otitis media | Malay | Herpes zoster infection | Severe congenital neutropenia | Antimicrobial prophylaxis | Alive | Heterozygous variant in ELANE gene (c.640G>T; p.Gly214Ter |
| (37) | 2 | Pt 1 (Girl) and Pt 2 (Male) | Pt 1 and Pt 2 are siblings presented at different time points over a 20-year span with raised IgE levels (NIH score: 39), recurrent infections, eczema, hypereosinophilia and bronchiectasis | Malay | Cryptococcus | DOCK8 Immunodeficiency | – | – | Pt 1 and Pt 2: Large deletion in DOCK8 starting from exon 30 to 48 Consanguineous parents + |
| (38) | 2 (Male) | – | – | – | – | Pt 1 and Pt 2: X-linked Agammaglobulinemia | IVIG replacement therapy | – | None |
| (39) | 1 (Female) | 12 years old | Recurrent fever, skin erythema and inflammatory arthritis | Malay | Staphylococcus aureus | Autoinflammatory disorder) NLRC4 mutation | – | Alive | Novel de novo heterozygous gain-of-function NLRC4 mutation (c.1970A>T, p.Gln657Leu) |
| (40) | 1 (Male) | – | Family history of Chronic Granulomatous Disease | Malay | – | Chronic Granulomatous Disease | – | Alive | None |
| (41) | 20 (3 patients were excluded due to duplicates with previous publications) | 144 months | A cohort of patients with Inborn error of immunity who underwent HSCT in University Malaya Medical Centre from 1993 – 2018. | – | – | Chronic Mucocutaneous Candidiasis | HSCT | Alive | No genetic mutations described in this cohort. |
| 9 months | – | – | Kostmann | HSCT | Alive | ||||
| 12 months | – | – | SCID | HSCT | Alive | ||||
| 15 months | – | – | SCID | HSCT | Alive | ||||
| 144 months | – | – | Bruton | HSCT | Alive | ||||
| 56 months | – | – | Wiskott–Aldrich Syndrome | HSCT | Died | ||||
| 102 months | – | – | Cyclical Neutropenia | HSCT | Alive | ||||
| 24 months | – | – | Wiskott–Aldrich Syndrome | HSCT | Alive | ||||
| 9 months | – | – | Chediak Higashi | HSCT | Alive | ||||
| 12 months | – | – | SCID | HSCT | Alive | ||||
| 8 months | – | – | Wiskott–Aldrich Syndrome | HSCT | Alive | ||||
| 7 months | – | – | SCID | HSCT | Alive | ||||
| 12 months | – | – | SCID (Omenn) | HSCT | Alive | ||||
| 6 months | – | – | SCID | HSCT | Alive | ||||
| 48 months | – | – | X-linked Inhibitor of Apoptosis Protein defect (XIAP) | HSCT | Alive | ||||
| 20 months | – | – | SCID (Omenn) | HSCT | Alive | ||||
| 17 months | – | – | Familial Hemophagocytic Lymphohistiocytosis | HSCT | Alive |
Primary Immunodeficiency Diseases Cases Reported in Malaysia.
BCG, Bacille Calmette-Guerin; HSCT, Hematopoietic stem cell transplantation; IVIG, Intravenous Immunoglobulin; NIH, National Institutes of Health; Pt, Patient; SCID, Severe combined immunodeficiency diseases.
A total of 119 PID cases were identified, and the diagnosis and distribution are illustrated in Figure 2. The most common forms of PID were immunodeficiencies affecting cellular and humoral immunity (30.3% of the cases published, Table 2), followed by predominantly antibody deficiencies (20.2%), congenital defects in phagocyte function and number (16.8%), diseases of immune dysregulation (10.9%), defects in intrinsic and innate immunity (3.4%), and autoinflammatory disorders (0.8%). The most common PID diagnosis was severe combined immunodeficiency (SCID, 22 patients), with genetic diagnosis available in 10 patients with SCID (Table 3). The second most common PID diagnosis was X-linked agammaglobulinemia (17 cases), followed by chronic granulomatous disease (CGD), affecting 14 patients (p47-phox-deficient CGD = three patients, X-linked CGD = two patients). The calculated prevalence rate was 0.37 cases per 100,000 population (from 1979 until 2019). We did not calculate the incidence as there was limited information in the literature.
Figure 2
Table 2
| PID category | N |
|---|---|
| Immunodeficiencies affecting cellular and humoral immunity | 36 (30.3%) |
| Severe Combined Immunodeficiency Disease | 22 |
| Combined T and B cell deficiencies | 2 |
| Hyper IgM Syndrome | 7 |
| DOCK8 deficiency | 2 |
| T cell deficiency—undefined | 3 |
| Combined immunodeficiencies with associated or syndromic features | 21 (17.6%) |
| Wiskott–Aldrich Syndrome | 10 |
| Ataxia telangiectasia | 1 |
| Di George/velocardio-facial Syndrome | 5 |
| Hyper-IgE Syndrome | 5 |
| Predominant antibody deficiencies | 24 (20.2%) |
| X-linked Agammaglobulinemia | 17 |
| Common variable immune deficiency | 3 |
| Selective IgA deficiency | 2 |
| CD19 deficiency | 1 |
| Undefined hypo-gammaglobulinemia | 1 |
| Disease of immune dysregulation | 13 (10.9%) |
| Hemophagocytic Lymphohistiocytosis | 6 |
| Chediak-Higashi Syndrome | 3 |
| Griscelli Syndrome (Type 2) | 1 |
| X-linked Lymphoproliferative Disorder | 2 |
| XIAP deficiency | 1 |
| Congenital defects of phagocyte number or function | 20 (16.8%) |
| Congenital Neutropenia | 6 |
| Leukocyte Adhesion Deficiency | 1 |
| Chronic granulomatous disease | 13 |
| Defects in intrinsic and innate immunity | 4 (3.4%) |
| IL12RB1 deficiency | 1 |
| Chronic Mucocutaneous Syndrome | 3 |
| Autoinflammatory disorders | 1 (0.8%) |
| Autoinflammatory disorder (NLRC4 mutation) | 1 |
Spectrum of PIDs, 1979–2020.
Table 3
| Diseases | Number of patients | Mutations identified |
|---|---|---|
| SCID | 2 | IL2RG |
| 1 | IL2RG c.270-2A>T | |
| 1 | ADA | |
| 1 | PNP | |
| 1 | TTC7A | |
| 1 | ZAP70 | |
| DOCK8 deficiency | 2 | Large deletion in DOCK8 starting from exon 30- 48 |
| WAS | 1 | WAS c.290C>T |
| 1 | WAS c.400C>A | |
| 1 | WAS g. 1115–1119 delC | |
| 1 | WAS c.28C>T | |
| 1 | WAS c.264C>A | |
| XLA | 1 | BTK g. IVS9+1G>C |
| 1 | BTK g. 36712A>G | |
| 1 | BTK c.1888A>T | |
| 1 | BTK g.34430_34447 delCAAAGTCATGATgtgagt | |
| CD19 Deficiency | 1 | CD19 c.24delC |
| Griscelli Syndrome (Type 2) | 1 | RAB27A c.550C>T |
| CGD | 2 | NCF1 |
| 1 | CYBB | |
| Congenital neutropenia | 1 | ELANE c.640G>T |
| Autoinflammatory syndrome | 1 | NLRC4 c.1970A>T |
Genetic mutations described.
Genetic tests are not universally available in Malaysia at present, and most are paid for by patients and families. Genetic mutation results were identified in 26 patients (21.8%; Table 3). Twenty-two patients underwent hematopoietic stem cell transplantation in Malaysia, whilst 19 received intravenous immunoglobulin replacement therapy. Only 28 patients were documented as alive, and 16 had died at the time of publication of the case reports. However, no data were available for the remaining publications.
In order to place results from Malaysia in context, a similar comparison of PID diseases frequencies was made, using published reports from other countries (Table 4). The prevalence of PID in Malaysia using this method is the lowest compared to reports from other nations. This low prevalence comes from a systematic review in the absence of national registry or cohort report, as reported by other countries.
Table 4
| Country | Malaysia | Singapore (42) | Korea (43) | Taiwan (44) | French (45)** | Brazil (46) | Kuwait (5) | USA (47) |
|---|---|---|---|---|---|---|---|---|
| Time of reporting | 1979–2020 | 1990–2000 | 2001–2005 | 1985–2004 | 2005–2009 | 1978–2011 | 2004–2018 | 1992–2020 |
| Types | Systematic review | Cohort report | National registry | National registry | National registry | Cohort report | National registry | National registry |
| Number of cases | 119 | 39 | 152 | 37 | 3,083 | 1,008 | 314 | 5,484 |
| Incidence | – | 2.65 per 100,000 live births | – | 2.17 per 100,000 livebirths | – | – | 24.96 per 100,000 | – |
| Prevalence | 0.37 cases per 100,000 population | – | 11.25 per million children | 1 in 46,000 live births | 4.4 per 100,000 inhabitants | – | *20.27 per 100,000 population | – |
| Consanguinity | 2.5% | Not reported | Not reported | 0% | 15% | Not reported | 78% | Not reported |
| Genetic mutations known | 21.7% | Not reported | Not reported | 16% | 40% | Not reported | 69% | 46% |
| Immunodeficiencies affecting cellular and humoral immunity | 30.3% | 10.3% | 13.2% | 11% | 17.2% | 6.7% | 31.8% | 9.6% |
| *T cell deficiencies 4.6% | *T cell deficiencies 19% | |||||||
| Combined immunodeficiencies with associated syndromic features | 17.6% | 12.8% | – | – | 14% | 8.3% | 21.7% | 20% |
| Predominantly antibody deficiencies | 20.2% | 41% | 53.3% | 46% | 42.8% | 60.8% | 17.8% | 49.2% |
| Diseases of immune dysregulation | 10.9% | – | – | – | 6.6% | 5.3% | 15% | 4.2% |
| Congenital defects of phagocyte number or function | 16.8% | 15.4% | 28.9% | 24% | 18.6% | 8.7% | 6.4% | 12% |
| Complement deficiencies | – | – | – | – | 0.5% | 2.9% | 7% | 0.5% |
| Autoinflammatory Syndromes | 0.8% | – | – | – | – | 1.3% | 0.3% | – |
| Defects of innate immunity | 3.4% | – | – | – | 0.2% | 5.9% | – | – |
| Others | – | 17.9% | – | – | – | – | – | 2.2% |
The comparison of primary immunodeficiencies prevalence, frequencies, consanguinity, and availability of genetic results with various countries.
Discussion
To the best of the authors' knowledge, this review is the first to study the prevalence of PIDs in Malaysia, which was 0.37 per 100,000 population. These rates were comparably lower than published rates from other countries, where the prevalence rate was ~4.4–20.27 per 100,000 population (5, 42–47).
In addition, these rates were lower than those in several neighboring countries in Southeast Asia with similar geo-political environments. Singapore has an incidence rate of 2.65 per 100,000 live births and an estimated occurrence rate of one in 37,000 live births (47). Thailand reported a cohort of 67 patients with PID from 18 year-experience from a single tertiary centre (48). No national PID patient registry databases are available in Southeast Asian countries. The only countries in the Asia Pacific with national PID registries are Japan, South Korea, Taiwan, Hong Kong, and China (49). The Middle East countries with national PID registries are Kuwait, Turkey, and Iran (5, 50, 51).
There was an increase in reporting over time which may be attributed to the increase in numbers of practicing clinical immunologists, enhanced diagnostic strategies, and facilities and improved awareness amongst medical fraternities locally (52).
This systematic review found that parental consanguinity was 2.5%, which was comparable with the parental consanguinity rate of 2.4% in a Malaysian population study on birth defects (53). Consanguineous marriage is not widely practiced in Malaysia compared with other South Asian and Middle East countries but is practiced in certain ethnic groups or indigenous populations.
This study is unique because it was not based on a national registry. However, it was the best attempt in delineating the prevalence rates of PIDs in Malaysia. Systematic review offers a non-biased approach to reviewing the evidence available in the absence of a national patient registry database. Furthermore, this systematic review is a novel approach in assessing PID prevalence in a low resource country that does not have a national database and a model that could be followed by other countries, such as in South America and Africa.
The potential limitations of this study were the calculations that were based on published evidence. The prevalence rate may not reflect the actual rate, because many PID cases are undiagnosed and, even if diagnosed correctly, not published. Furthermore, reporting bias possibly existed, where certain diagnoses were reported more than others. This bias could explain why the most common PID diagnoses in this systematic review were severe combined immunodeficiencies rather than primary antibody defects, which are more prevalent in patient registry databases worldwide. Furthermore, only two adult patients were reported, and only three Common Variable Immunodeficiency cases were published, thereby emphasizing that the lack of clinical immunologists to take care of adult patients may be a major contributing factor for low adult PID cases diagnosed or not reported.
Therefore, a national PID registry database must be urgently established in Malaysia. Inter-collaboration between various agencies is the manner to move forward in terms of improving access to early diagnosis and treatment of PIDs in Malaysia.
Conclusions
The prevalence of PID is lower in Malaysia than in other geographical regions. The comparison of PID prevalence between countries may be misleading due to various case-finding strategies. Efforts should be geared toward setting up a national PID patient registry database in Malaysia.
Statements
Data availability statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.
Author contributions
NA, IH, and ZZ performed the literature search, reviewed the title, and abstracts independently and conducted the stratifications. IA and NA conducted the data extraction of relevant studies. Any disagreements/clarifications were confirmed with AG. The prevalence rates were calculated by EM. IA wrote the first draft of the manuscript. All authors designed the study. All authors critically reviewed the literature search and revised the manuscript. All authors read and approved the final version of the manuscript.
Funding
Grant Agencies: Universiti Sains Malaysia Grant Name: USM 2020 Initiatives (Project 19) Grant Number: 311.CIPPT.411919.
Acknowledgments
The authors wish to acknowledge USM for the financial and moral support in PID service empowerment through the USM 2020 Initiatives (Project 19) (USM: 311.CIPPT.411919), Puan Noraida Hassan (Librarian, Hamdan Tahir Library, USM) for assistance in conducting the database searches and thank all the original authors that responded and supplied the manuscript with more details.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2020.01923/full#supplementary-material
References
1.
RezaeiNAghamohammadiANotarangeloLD. Primary Immunodeficiency Diseases: Definition, Diagnosis, and Management. 2nd ed. Berlin: Springer-Verlag Berlin Heidelberg (2017).
2.
BousfihaAAJeddaneLAilalFBenhsaienIMahlaouiNCasanovaJLet al. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. (2013) 33:1–7. 10.1007/s10875-012-9751-7
3.
Department of Statistics Malaysia. (2019). Retrieved from: https://www.dosm.gov.my (December 7, 2019).
4.
Condino-NetoAEspinosa-RosalesFJ. Changing the lives of people with Primary Immunodeficiencies (PI) with early testing and diagnosis. Front Immunol. (2018) 9:1439. 10.3389/fimmu.2018.01439
5.
WaleedAHAl-AhmadMAl-KhabazAHusainASadekAOthmanY. The Kuwait national primary immunodeficiency registry 2004-2018. Front Immunol. (2019) 10:1754. 10.3389/fimmu.2019.01754
6.
El-HelouSMBiegnerAKBodeSEhlSRHeegMMaccariMEet al. The German National Registry of primary immunodeficiencies (2012-2017). Front Immunol. (2019) 10:1272.
7.
TangyeSGAl-HerzWBousfihaAChatilaTCunningham-RundlesCEtzioniAet al. Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. (2020) 40:24–64. 10.1007/s10875-019-00737-x
8.
TongYHSinniahDMurugasuRWhiteJ. (1979) Two Malaysian Chinese male children with the Wiskott-Aldrich syndrome. Singapore Med J. 20:355–9.
9.
NohLMLowSMLajinIAbdullahN. Antibody deficiency with hyper IgM-a case report. Malaysian J Pathol. (1992) 14:121–23.
10.
NohLMNoahRMWuLLNasuruddinBAJunaidahEOoiCPet al. Chronic granulomatous disease–a report in two Malay families. Singapore Med J. (1994) 35:505–8.
11.
SendutIHAriffinHSinniahD. Cryptococcal meningitis in a patient with hyperimmunoglobulin E syndrome. Malaysian J Child Health. (1995) 7:145–7.
12.
HanyAThongMKLinHP. Two brothers in a Malaysian family with X-linked lymphoproliferative disease - a case report. Singapore Med J. (1996) 37:325–7.
13.
LeongCFCheongSKHamidahNHAinoonOKannaheswaryY. Serum ferritin and lactate dehydrogenase in a case of hemophagocytic lymphohistiocytosis. Malaysian J Pathol. (1998) 20:103–8.
14.
LeeWSBoeyCCGohAY. Pulmonary nocardiosis in a child with hyperimmunoglobulin E syndrome. Singapore Med J. (1999) 40:278–80.
15.
LeeWSPuthuchearySDParasakthiN. Extra-intestinal non-typhoidal Salmonella infections in children. Ann Trop Paediatr. (2000) 20:125–9. 10.1080/02724936.2000.11748121
16.
JinYMazzaCChristieJRGilianiSFioriniMMellaPet al. (2004) Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation. Blood. 104:4010–910.1182/blood-2003-05-1592
17.
GanGGEowGITehANgSCSangkarJV. Familial hemophagocytic lymphohistiocytosis in two brothers. Med J Malaysia. (2004) 59:100–2.
18.
AriffinHLumSHCheokSAShekharKAriffinWAChanLPet al. Haemophagocytic lymphohistiocytosis in children. J Paediatr Child Health. (2005) 41:136–9. 10.1111/j.1440-1754.2005.00564.x
19.
SureisenMChoonSKTaiCC. Recurrent Chromobacterium violaceum infection in a patient with chronic granulomatous disease. Med J Malaysia. (2008) 63:346–7.
20.
LeePPChanKChenTJiangLWangX Zeng et al. Molecular diagnosis of severe combined immunodeficiency-identification of IL2RG, JAK3, IL7R, DCLRE1C, RAG1, and RAG2 mutations in a cohort of Chinese and Southeast Asian Children. J Clin Immunol. (2010) 31:281–96. 10.1007/s10875-010-9489-z
21.
NohLMAbd HamidIRus AnidahAHashimINarazahYLatiffAHet al. An CD19 deficient B cell abnormality and selective isotype IgM deficiency in A Malay Child. A Case Report. In: Proceeding of the 15th Meeting of the European Society Immunodeficiencies-ESID. (2012). Retrieved from: https://www.researchgate.net/publication/236946449_An_CD19_Deficient_B_Cell_Abnormality_and_Selective_isotype_IgM_deficiency_in_A_Malay_Child_A_Case_Report
22.
GillHKKumarHCDhaliwalJSZabidiFSendutIHNoahRet al. Defining p47-phox deficient chronic granulomatous disease in a Malay family. Asian Pac J Allergy Immunol. (2012) 30:313–20.
23.
GillHKKumarHCChengCKMingCCNallusamyRYusoffNet al. De chronic granulomatous disease in a male child with an X-CGD carrier, Klinefelter brother. Asian Pac J Allergy Immunol. (2013) 31:167–72. 10.12932/AP0274.31.2.2013
24.
NohLMNasuruddinBAAbdul LatiffAHNoahRMKamarul AzaharMRNorzilaMet al. Clinical-epidemiological pattern of primary immunodeficiencies in Malaysia 1987-2006: a 20 year experience in Four Malaysian Hospitals. Med J Malaysia. (2013) 68:13–17.
25.
RashidZAliUSulongARahmanR. Chromobacterium Violaceum infections; a series of case reports in a Malaysian Tertiary Hospital. Internet J Infect Dis. (2013) 11:1–6. 10.5580/2cd3
26.
ChearCTGillHKRamlyNHDhaliwalJSBujangNRipenAMet al. A novel Bruton's tyrosine kinase gene (BTK) invariant splice site mutation in a Malaysian family with X-linked agammaglobulinemia. Asian Pac J Allergy Immunol. (2013) 31:320–4. 10.12932/AP0304.31.4.2013
27.
AriffinHGeikowskiAChinTFChauDArshadAAbu BakarKet al. Griscelli syndrome. Med J Malaysia. (2014) 69:193–4.
28.
BaharinMFBegumSIbrahimKSongYAPAbdul ManafAMRipenAMet al. Molecular characterization of two Malaysian patients with Wiskott-Aldrich syndrome. Malaysian J Pathol. (2015) 37:153–8.
29.
ChearCTRipenAMMohamedSASDhaliwalJS. A novel BTK gene mutation creates a de-novo splice site in an X-linked agammaglobulinemia patient. Gene. (2015) 560:245–8. 10.1016/j.gene.2015.02.019
30.
YangWLeePPW Thong M-K RamanujamTMShanmugamAKohMTet al. (2015). Compound heterozygous mutations in TTC7A cause familial multiple intestinal atresias and severe combined immunodeficiency. Clin Genet.88:542–9. 10.1111/cge.12553
31.
IsmailIHJamliFMOthmanISNohLMAbdul LatiffAH. Malaysia's first transplanted case of chronic granulomatous disease: the journey of overcoming obstacles. Children (Basel). (2016) 3:9. 10.3390/children3020009
32.
MirsafianHRipenAM Leong W-M ChearCTBin MohamadSet al. Transcriptome profiling of monocytes from XLA patients revealed the innate immune function dysregulation due to the BTK gene expression deficiency. Sci Rep. (2017) 7:6836. 10.1038/s41598-017-06342-5
33.
LukADWLeePPMaoHChanK-WChenXYChenT.-Xet al. Family history of early infant death correlates with earlier age at diagnosis but not shorter time to diagnosis for severe combined immunodeficiency. Front Immunol. (2017) 8:808. 10.3389/fimmu.2017.00808
34.
NgaiJJChongKLOli MohamedS. Cytomegalovirus retinitis in primary immune deficiency disease. Case Rep Ophthalmol Med. (2018) 2018:8125806. 10.1155/2018/8125806
35.
AriffinHChewKSJawinVThavagnanamS. T-cell replete haploidentical bone marrow transplantation for X-linked severe combined immunodeficiency. Singapore Med J. (2018) 61:285–6. 10.11622/smedj.2018101
36.
MohamadSMAbd HamidIJAbdul WahabAAliAChooCMBakonFet al. Submission ID#600349: severe congenital neutropenia caused by ELANE gene mutation in a Malaysian girl. J Clin Immunol. (2019) 39(Suppl) 1–151.
37.
Abd HamidIJNik YusoffNKDaudMMohamadSMHashimIFZainudeenZTet al. Submission ID#605833: DOCK8 immunodeficiency in a Malay family from Malaysia: a family study. J Clin Immunol. (2019) 39:1–151.
38.
El-SayedZAAbramovaIAldaveJCAl-HerzWBezrodnikLBoukariRet al. X-linked agammaglobulinemia (XLA): phenotype, diagnosis, and therapeutic challenges around the world. World Allergy Organ J. (2019) 12:100018. 10.1016/j.waojou.2019.100018
39.
ChearCTNallusamyRScottWCChanKCBaharinMFHishamshahMet al. A novel de novo NLRC4 mutation reinforces the likely pathogenicity of specific LRR domain mutation. Clin Immunol. (2020) 211:108328. 10.1016/j.clim.2019.108328
40.
ZainudeenZTHashimIFAbd HamidIJ. Chronic granulomatous diseases. Malaysian J Paediatr Child Health. (2020) 25:28–9.
41.
AriffinHAb RahmanSJawinVFooJCAmramNFMahmoodNMet al. Haematopoietic stem cell transplantation for inborn errors of immunity: 25-year experience from University of Malaya Medical Centre, Malaysia. J Paediatr Child Health. (2019) 56:379–83. 10.1111/jpc.14621
42.
LimDLThongBYHoSYShekLPLouJLeongKet al. Primary immunodeficiency diseases in Singapore-the last 11 years. Singapore Med J. (2003) 44:579–86.
43.
RhimJWKimKHKimDSKimBSKimJSKimCHet al. Prevalence of primary immunodeficiency in Korea. J Korean Med Sci. (2012) 27:788–93. 10.3346/jkms.2012.27.7.788
44.
LeeWIKuoMLHuangJLLinSJWuCJ. Distribution and clinical aspects of primary immunodeficiencies in a Taiwan pediatric tertiary hospital during a 20-year period. J Clin Immunol. (2005) 25:162–73. 10.1007/s10875-005-2822-2
45.
The French national registry of primary immunodeficiency diseases. Clin Immunol. (2010) 135:264–72. 10.1016/j.clim.2010.02.021
46.
Carneiro-SampaioMMoraes-VasconcelosDKokronCMJacobCMToledo-BarrosMDornaMBet al. Primary immunodeficiency diseases in different age groups: a report on 1,008 cases from a single Brazilian reference center. J Clin Immunol. (2013) 33:716–24. 10.1007/s10875-013-9865-6
47.
Total number of patients in the USIDNET registry. US Immunodeficiency Network. (2020). Available online at: http://www.usidnet.org/index.cfm (Accessed June 20, 2020).
48.
BenjasupattanananPSimasatheinTVichyanondPLeungwedchakarnVVisitsunthornNPacharnPet al. Clinical characteristics and outcomes of primary immunodeficiencies in Thai children: an 18-year experience from a tertiary care center. J Clin Immunol. (2009) 29:357–64. 10.1007/s10875-008-9273-5
49.
PilaniaRKChaudharyHJindalAKRawatASinghS. Current status and prospects of primary immunodeficiency diseases in Asia. Genes Dis. (2020) 7:3–1110.1016/j.gendis.2019.09.004
50.
AbolhassaniHKiaeeFTavakolMChavoshzadehZAlirezaSMomenTet al. Fourth update on the Iranian national registry of primary immunodeficiencies: integration of molecular diagnosis. J Clin Immunol. (2018) 38:816–32. 10.1007/s10875-018-0556-1
51.
KilicSSOzelMHafizogluDKaracaNAksuGKutukculerN. The prevalances and patient characteristics of primary immunodeficiency diseases in Turkey-two centers study. J Clin Immunol. (2013) 33:74–83. 10.1007/s10875-012-9763-3
52.
Abd HamidIJZainudeenZTHashimIF. Current perspectives and challenges of primary immunodeficiency diseases in Malaysia. Malaysian J Paediatr Child Health. (2020) 25:16.
53.
ThongMKHoJJKhatijahNN. A population-based study of birth defects in Malaysia. Ann Hum Biol. (2005) 32:180–7. 10.1080/03014460500075332
Summary
Keywords
primary immunodeficiency, inborn error of immunity, epidemiology, prevalence, Malaysia
Citation
Abd Hamid IJ, Azman NA, Gennery AR, Mangantig E, Hashim IF and Zainudeen ZT (2020) Systematic Review of Primary Immunodeficiency Diseases in Malaysia: 1979–2020. Front. Immunol. 11:1923. doi: 10.3389/fimmu.2020.01923
Received
22 May 2020
Accepted
17 July 2020
Published
26 August 2020
Volume
11 - 2020
Edited by
Waleed Al-Herz, Kuwait University, Kuwait
Reviewed by
Antonio Condino-Neto, University of São Paulo, Brazil; Nizar Mahlaoui, Assistance Publique Hopitaux De Paris, France
Updates
Copyright
© 2020 Abd Hamid, Azman, Gennery, Mangantig, Hashim and Zainudeen.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Intan Juliana Abd Hamid intanj@usm.my
This article was submitted to Primary Immunodeficiencies, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.